A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics

CTTQ

Status and phase: Unknown; Phase 1

Conditions: Advanced Cancer

Treatments: Drug: TQ-B3101

Study type: Interventional

Funder types: Industry

Identifiers

NCT03019276

TQ-B3101-1-0001

Details and patient eligibility

About

To study the pharmacokinetic characteristics of TQ-B3101 in the human body, recommend a reasonable regimen for subsequent research.

Full description

single arm, single or repeat dosing of TQ-B3101 on patients with solid tumors.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histological documentation of Advanced solid tumors
• Lack of the standard treatment or treatment failure
• 18-70years,ECOG PS:0-1,Life expectancy of more than 3 months
• Main organs function is normal
• Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped
• Patients should participate in the study voluntarily and sign informed consent

Exclusion criteria

• Patients with treatment failure by ALK/ROS1 inhibitor
• Patients with anti-teratment,radiotherapy or surgery within 4 weeks
• Patients participated in other anticancer drug clinical trials within 4 weeks or ALK/ROS1 inhibitor within 1 week
• Blood pressure unable to be controlled(systolic pressure>140 mmHg，diastolic pressure>90 mmHg). Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QT≥470ms)
• Patients with non-healing wounds or fractures
• Patients with drug abuse history and unable to get rid of or Patients with mental disorders
• History of immunodeficiency
• Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

TQ-B3101

Experimental group

Description:

TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent

Treatment:

Drug: TQ-B3101